GlassScriptPhysician profile
Carmel Hensley
NPI 1174918544
$5,110.87
in general payments reported to CMS, 2019-2025
47 companies · $1,770 in 2025
The $1,770 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $403 · 2022: $629 · 2023: $1,420 · 2024: $890 · 2025: $1,770.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,996 · Education: $83.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,995.64 |
| Education | $83.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $857.72 | 2021-2025 | |
| Novo Nordisk INC | $560.86 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $494.02 | 2021-2025 | Mounjaro, Jardiance, Trulicity |
| Novartis Pharmaceuticals Corporation | $307.35 | 2021-2025 | |
| Amgen INC. | $285.55 | 2021-2025 | Repatha, Otezla, Uplizna |
| Pfizer INC. | $282.71 | 2021-2025 | |
| Lundbeck LLC | $250.76 | 2025 | Vyepti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $182.64 | 2023-2025 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $178.60 | 2022-2023 | |
| Abbott Laboratories | $162.73 | 2023-2025 | Cardiomems, Freestyle Libre 3 |
| Axsome Therapeutics, INC. | $156.43 | 2023-2024 | Auvelity |
| Janssen Biotech, INC. | $142.36 | 2021-2025 | |
| Ucb, INC. | $123.83 | 2021-2025 | Rystiggo, Zilbrysq |
| Phathom Pharmaceuticals, INC. | $119.84 | 2024-2025 | Voquezna |
| Biohaven Pharmaceutical Holding Company LTD. | $119.04 | 2022 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carmel Hensley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.